The following HTML text is provided to enhance online
readability. Many aspects of typography translate only awkwardly to HTML.
Please use the page image
as the authoritative form to ensure accuracy.
Vaccines for the 21st Century: A Tool for Decisionmaking
Table A12–2 Disease Scenarios for Influenza A and B Infection
No. of Cases
% of Cases
Committee HUI Values
Duration (years)
Moderate to severe respiratory illness
45,264,867
83.30%
bed rest
0.75
0.0082 (3 days)
discomfort following bed rest
0.90
0.0384 (14 days)
Respiratory illness with sinusitis
5,325,278
9.80%
bed rest
0.75
0.0082 (3 days)
sinusitis
0.75
0.0192 (7 days)
discomfort following bed rest
0.90
0.0192 (7 days)
Respiratory illness w/post-influenza fatigue
2,662,639
4.90%
bed rest
0.75
0.0082 (3 days)
discomfort following bed rest
0.90
0.0384 (14 days)
post-influenza fatigue
0.87
0.2466 (90 days)
Pneumonia
978,112
1.80%
acute care hospitalization
0.65
0.0274 (10 days)
recuperation
0.90
0.0384 (14 days)
Pneumonia—ICU
108,679
0.20%
ICU hospitalization
0.52
0.0274 (10 days)
recuperation
0.90
0.0384 (14 days)
Exacerbation of underlying asthma/heart disease
54,340
0.10%
0.53
0.0233 (8.5 days)
that everyone requiring bed rest for acute influenza infection incurs costs for an over-the-counter symptomatic treatment. The cost calculations include one visit to a physician and a prescription medication for 20% of the patients during the acute phase. Recovery phases were assumed to include costs for over-the-counter medications and physician visits for some of the patients with sinusitis and post-influenza fatigue. Hospitalization costs, diagnostics, inpatient and with outpatient physician visits, and medications were included costs for patients with pneumonia. There were no costs calculated for the exacerbation of underlying chronic disease states by influenza infection with pneumonia.
